Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SMMT
SUMMIT THERAPEUTICS INC.
NASDAQ
$13.73
▼ DOWN 4.19% (-0.60)

KEY STATISTICS

Market Cap$10.95 B
52w High$29.23
52w Low$12.07
Dividend Yield—
Frequency—
P/E-12.26
Volume3.89M
Shares Out.797.75M

COMPANY

LEADERSHIP

Robert W. Duggan
CHIEF EXECUTIVE
Robert W. Duggan

COMPENSATION 2026

Salary$0
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$172,376
Total$172,376

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 5, 2015
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
265

PRICE TARGET

Target High$38.00
Target Low$11.90
Target Median$19.50
Target Consensus$23.65

UPCOMING EARNINGS

DateOct 19, 2026
DayMonday
Rev. Est.$71.43K
OCT
19
MON

PRICE

$13.73 ▼ DOWN 4.19% (−$0.60)
$13.50$13.75$14.00$14.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.73

About Summit Therapeutics Inc.

https://www.smmttx.com ↗

Summit Therapeutics Inc. is a biopharma firm developing antibiotics like ridinilazole for infectious diseases, mainly CDI, in the U.S. and Latin America.

INDUSTRY

Biotechnology

A PRODUCT SUMMIT THERAPEUTICS INC. IS KNOWN FOR

Ivonescimab (SMT112)
Ivonescimab (SMT112)

Ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF, is in Phase III trials for cancer, including NSCLC, with a BLA submission to the FDA.

COMPETITORS

COMPETITOR
BMY COMPARE
BNTX COMPARE
MRK COMPARE
PFE COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ1-2022Q2-2022Q3-2022Q4-2022
License and Service$250K $235K ▼$220K ▼$3.97M ▲

Revenue by Geography

MapREGIONQ4-2021Q1-2022Q2-2022Q3-2022
Latin America$251K $250K ▼$235K ▼$220K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
117
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.95% · 7.9M
VTS.AX
0.00% · 3.7M
IBB
0.12% · 1.0M
PINK
1.97% · 538.4K
SCHM
0.04% · 426.7K
LABU
0.65% · 288.1K
QQQJ
0.28% · 235.2K
ONEQ
0.03% · 192.2K
CANC
0.97% · 150.0K
ZUH.TO
1.00% · 95.3K
BBMC
0.04% · 60.3K
PTL
0.06% · 36.9K
BIB
0.38% · 27.7K
JHMM
0.01% · 26.8K
CURE.AX
0.95% · 24.5K
BBC
0.61% · 22.4K
BKMC
0.05% · 21.6K
IQSM
0.06% · 15.1K
RECS
0.00% · 12.0K
TILT
0.00% · 5.3K
GUSA
0.00% · 4.4K
VETS
0.23% · 4.0K
TNXT
0.23% · 3.0K
STXV
0.01% · 697
MN
MNZL
0.00% · 98
MHIP
0.00% · 84

INSTITUTIONAL OWNERSHIP

SHARES OWNED
14.98%
HOLDERS
361
TOP 12 OF 361 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
36.4M sh · $636.48M
Fmr LLC
13.4M sh · $233.68M
Vanguard Group Inc
11.4M sh · $235.11M
Blackrock, Inc.
9.7M sh · $183.04M
State Street Corp
9.5M sh · $138.95M
Price T Rowe Associates Inc /Md/
9.4M sh · $163.91M
Blackrock Inc.
7.9M sh · $61.61M
Ubs Group AG
5.2M sh · $76.26M
Polar Capital Llp
5.0M sh · $17.2M
Goldman Sachs Group Inc
4.5M sh · $65.76M
Point72 Asset Management, L.P.
3.7M sh · $53.88M
Geode Capital Management, LLC
3.4M sh · $49.95M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CO-CHIEF EXECUTIVE OFFICER
DUGGAN ROBERT W
Purchase · 3.8M shares
2026-06-12
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Zanganeh Mahkam
Purchase · 3.8M shares
2026-06-12
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Zanganeh Mahkam
Purchase · 100.0K shares
2026-06-04
★
DIRECTOR, OFFICER: COO AND CFO
Soni Manmeet Singh
Purchase · 25.0K shares
2026-06-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
MARKET PERFORM 2
NEUTRAL 2
MARKET OUTPERFORM 2
HOLD 1
EQUAL WEIGHT 1
OVERWEIGHT 1
12 GRADES IN THE LAST 12 MONTHS
Bernstein MARKET PERFORM HC Wainwright & Co. NEUTRAL Leerink Partners MARKET PERFORM Guggenheim BUY Stifel BUY Piper Sandler NEUTRAL Jefferies HOLD Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
MRNA$137.99COMPARE
RVMD$207.88COMPARE
RPRX$60.85COMPARE
ROIV$34.71COMPARE
ASND$247.91COMPARE
BBIO$76.60COMPARE
UHS$171.66COMPARE
IONS$61.05COMPARE